DNA synthesis inhibitors: Fluoroquinolones

27,484views

DNA synthesis inhibitors: Fluoroquinolones

Pharma

Pharma

Introduction to pharmacology
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Cholinergic receptors
Adrenergic receptors
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Sympathomimetics: Direct agonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Atypical antidepressants
Typical antipsychotics
Atypical antipsychotics
Lithium
Nonbenzodiazepine anticonvulsants
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Antihistamines for allergies
Acid reducing medications
Laxatives and cathartics
Antidiarrheals
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Glucocorticoids
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Mechanisms of antibiotic resistance
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Osteoporosis medications
General anesthetics
Local anesthetics
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Opioid antagonists
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
Androgens and antiandrogens
PDE5 inhibitors
Estrogens and antiestrogens
Progestins and antiprogestins
Aromatase inhibitors
Uterine stimulants and relaxants
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors

Transcript

Watch video only

Content Reviewers

Our bodies consist of eukaryotic cells, while bacterias consist of prokaryotic cells.

So, in order to treat bacterial infections we can develop antimicrobials that only target prokaryotic cells while leaving our cells mostly unharmed.

One of these targets is bacterial DNA, and we call these medications DNA inhibitors or nucleic acid inhibitors.

There are plenty of processes and enzymes involved that we can target and the quinolones and fluoroquinolones inhibit an enzyme called DNA topoisomerase.

So there are many different types of topoisomerases but we’ll be looking at topoisomerase II, also called DNA gyrase, and topoisomerase IV.

Both types of topoisomerases cause double strand breaks in DNA, but at different points during mitosis.

Topoisomerase II plays a role in condensing the chromosomes by making a double strand break in the DNA so that it can be more tightly wound, causing a supercoil.

When enough supercoils are induced, the DNA condenses.

Topoisomerase IV plays a role later on, after the chromosome has been replicated, where it causes a double strand break in the DNA so the new DNA strand can be disentangled from the original.

Now, quinolones are created to target bacterial topoisomerases, but it was soon discovered that by adding a fluorine molecule to the quinolones, they become more effective.

So these newer medications, called fluoroquinolones, replaced the older quinolones in most clinical settings.

Common fluoroquinolones include ciprofloxacin, ofloxacin, balofloxacin, levofloxacin, gemifloxacin, and moxifloxacin.

One way to tell a fluoroquinolone apart from other antimicrobials is that they all have the suffix “-floxacin.”

These medications can be taken peroral or via IV, but ciprofloxacin and ofloxacin are also available in otic formulations, while moxifloxacin is also available in ophthalmic solutions.

Now fluoroquinolones are broad spectrum bactericidal antibiotics and ciprofloxacin in particular is widely used.

They are very effective against gram negative bacterias like Enterobacteriaceae, Haemophilus, Legionella, Neisseria, Moraxella, and even Pseudomonas species.

They are also effective against certain mycobacteria and can be used for the treatment of tuberculosis.

However, more and more bacteria are becoming resistant to ciprofloxacin, either through mutations in the genes that code of topoisomerases, or through efflux pumps that pump the medication out.

Another downside is that the older fluoroquinolones are less effective against Gram positive bacteria, but the newer ones, like levofloxacin, gemifloxacin, and moxifloxacin, have improved effectiveness against Gram positive cocci, especially Streptococcus pneumoniae, so they are called respiratory fluoroquinolones since they are often used to treat hospital acquired pneumonia.

The trade off is that they are less effective against pseudomonas than ciprofloxacin.

Most fluoroquinolones are not effective against MRSA.

As a general rule, fluoroquinolones should not be taken perorally together with mineral supplements like iron, zinc, or calcium pills.

They’ll bind to each other, a process called chelation, preventing their absorption from the gut.

They are metabolized in the liver by a family of enzymes called cytochrome p450, but they are also inhibitors of this enzyme.

For side effects, fluoroquinolones can cause tendonitis especially in the achilles tendon, where they can cause it to rupture.

Due to this, they should not be used by active athletes and the elderly.